



# The Canadian Vaccine Catalogue

**Working Group Meeting**

June 29, 2021

# Agenda




1. Welcome and CVC release update
2. COVID-19 Terminology Discussion
  - a. COVID-19 terminology updates since last meeting
  - b. Questions for the group
    - i. Generic concepts for vaccine products administered outside of Canada
    - ii. Other RFCs/concepts needed to support international COVID-19 vaccines
3. Lot/expiry cadence and source - Helen (BCCDC)
4. Other RFC updates
5. CVC & GS1 - Rob Bell (GS1 Canada)
6. Wrap up and questions

# 1. Release Update

- CVC version 1.1.11 to be released today, which includes:
  - COVID-19 vaccine lot/expiry information up until June 28, 2021
  - All vaccine product lot/expiry information for May 2021
  - Updates to COVID-19 vaccine shelf status
    - Under review (Medicago, Novavax)
    - Authorized by interim order (Janssen)
    - Marketed (Pfizer, Moderna, AstraZeneca, COVISHIELD)
  - Updated FSN and Display Term for COVID-19 protein subunit generic concept
  - Updates to shelf status for select products to align with DPD
  - Addition of Pharmacy Intern to HealthCareProviderRoleType subset
  
- Next CVC release (Version 1.1.12)
  - July 28th, 2021

# 2a. COVID-19 Terminology: Concepts created to date

COVID-19 Terminology Hierarchy



## 2a. International COVID-19 Vaccine Terminology

### Trade Name Concept - Sinovac COVID-19 Vaccine

ConceptID	TBD
<b>Proposed Concept Name</b>	CoronaVac 0.5 milliliter suspension for injection Sinovac Biotech Limited
<b>Proposed Preferred Term</b>	COVID-19 CoronaVac SIN

### Trade Name Concept - Sinopharm COVID-19 Vaccine

ConceptID	TBD
<b>Proposed Concept Name</b>	COVID-19 vaccine BIBP 0.5 milliliter suspension for injection Sinopharm and Beijing Institute of Biological Products Co-Ltd
<b>Proposed Preferred Term</b>	COVID-19 COVID-19 vaccine BIBP SINOPHARM and BIBP

## 2a. International COVID-19 Vaccine Terminology

### Generic Concept - COVID-19 inactivated virus

ConceptID	TBD
<b>Concept Name</b>	Vaccine product containing only inactivated whole Severe acute respiratory syndrome coronavirus 2 antigen
<b>Preferred Term</b>	COVID-19 inactivated virus unspecified

## 2b. COVID-19 Terminology Questions

1. **Question/discussion:** for COVID-19 vaccines not licensed in Canada, any objections to creating more generic concepts for each type of vaccine to provide historical information (i.e. without specifications on the dose, form, strength or MAH/manufacturer)?
2. **Question:** any other RFCs we should be submitting for COVID-19 vaccines not licensed in Canada?
  - a. Request to add Sputnik V (currently under review by WHO)

## 3. Lot/expiry data in the CVC

Agenda item from BC (Helen):

- Group discussion on cadence and source of lot numbers & possibility to receive more timely updates from Health Canada

## 4. Other RFC Updates

Proposal to submit RFCs (request to change the concept) to align with what is presented in the DPD:

ConceptID	FSN	Change
7191000087105	ROTARIX 1000000 units per milliliter oral suspension GlaxoSmithKline Inc. (product)	Update strength: 1000000 units per 1.5 milliliter...
7231000087104	VARILRIX 3300000 plaque forming units per 0.5 milliliter powder and diluent for solution for injection GlaxoSmithKline Inc. (product)	Update strength: 2000 plaque forming units per 0.5 milliliter...

## 4. Other RFC Updates

Proposal to submit RFCs (new concept) to align with what is presented in the DPD:

<b>Vaccine Product</b>	<b>Shelf Status</b>
HYPERRAB (DIN: 02486571) GRIFOLS THERAPEUTICS	Marketed

## 5. CVC & GS1 Canada

Presentation by Rob Bell, Director, Healthcare at GS1 Canada

# 6. Wrap up and Questions

- Next CVC Meeting
  - Thursday, July 29th, 2021 from 2-3PM EST
  - Register in advance for this meeting:  
<https://infoway-inforoute.zoom.us/meeting/register/tJMlcuChpzkoGNDTahDdmMaPc-8EvNJK3bYM>